Skip to main content


Ongoing Private
Sector Projects

The following projects are currently being completed by DAS. Projects are listed in the order in which Research Ethics Board approval was obtained.

Client: IQVIA Solutions Canada Inc.

Project ID: P2018-040/2020 0970 173 000

Research Question/Objectives: In December 2015, mepolizumab, was approved in Canada as add-on maintenance for the treatment of adult patients with uncontrolled eosinophilic severe asthma. Despite compelling clinical trial evidence, many stakeholders still seek to better understand if the value seen in randomized studies is realized in actual clinical practice. Now, with over two years of real-world data available, this study would like to investigate the real-world impact of mepolizumab on asthma related clinical outcomes, healthcare resource use and costs among severe asthma patients, outside of the randomized clinical trial setting. The objective of the current research project primarily is to estimate the demographic and cliccal characteristics of real-world mepolizumab patients. The project team is also interested in comparison of asthma related real-world outcomes of post-mepolizumab initiation versus pre-mepolizumab initiation.

Research objectives

Primary Objectives:

  • Describe the demographic and clinical characteristics of real-world mepolizumab patients to understand the population with mepolizumab utilization.
  • Compare asthma-related real-world outcomes (listed below) for mepolizumab patients (post-mepolizumab initiation) versus pre-mepolizumab initiation among the same patients to determine the effectiveness of mepolizumab in actual clinical practice.
  • Compare costs associated with asthma-related real-world outcomes for mepolizumab patients (post-mepolizumab initiation) versus pre-mepolizumab initiation among same patients to evaluate the differences from the public payer’s perspective.

Secondary Objective:

  • Investigate the real-world asthma-related outcomes and associated costs (as listed above under primary objectives) for highly adherent (≥ 9 injections) mepolizumab patients (i.e. sub cohort) post versus premepolizumab initiation to understand the impact of mepolizumab among patients who are highly adherent.

Availability of Results: study in progress

Client: Janssen Inc.

Project ID: P2019-060/2020 0970 193 000

Research Question/Objectives: Patients with advanced prostate cancer may experience a myriad of complications which may contribute to significant morbidity and health care cost. The team is interested in examining whether there are geographic variations in the manner in which patients are managed or the type of therapy they receive. In clinical trials, many patients receive many lines of therapy (often 2 or three) but it is not clear whether this occurs generally in Ontario - understanding this will aid in assessing the generalizability of trial results to the Ontario population. The research team is also interested in understanding how physicians order tests for the monitoring and investigation of patients with advanced prostate cancer, both to assess the appropriateness of test utilization for resource stewardship and to assess the potential for delays in diagnosis due to underutilization. The team seeks to characterize these by assessing physician interactions, hospitalizations, procedures, and prescriptions. Finally, utilizing data from OLIS, allows an assessment of the association between common laboratory test and survival in advanced patients with prostate cancer. Validation in the ICES dataset would prove generalizability and lend credibility to the use of these common, low-cost tests, which may improve patient risk stratification and counseling.

Research objectives:

  • Understanding geographic variations in care for men with advanced prostate cancer, including consultation with a medical oncologist, consultation with a radiation oncologist, receipt of local therapy, receipt of newer anti-cancer agents, receipt of multi lines of systemic therapy.
  • Characterizing the common sequences of systemic therapy used in patients with advanced prostate cancer.
  • Understand practice patterns for physicians treating advanced prostate cancer including frequency of laboratory tests and imaging tests.
  • Understand characteristics, complications, and treatments of patients with advanced prostate cancer.
  • Examine the prognostic role of common lab tests on survival of patients with advanced prostate cancer.

Availability of Results: study in progress

Client: AstraZeneca Canada/Broadstreet Health Economics

Project ID: P2020-069/2021 0970 226 000

Research Question/Objectives: The overall aim is to understand the impact of chronic obstructive pulmonary disease (COPD) exacerbations and the pattern of treatment to characterize disease trajectory and burden of disease among COPD patients in Canada, over time, from diagnosis to death, and how this may differ by treatment patterns. To characterize the frequency and time to exacerbations and other acute and chronic comorbidities, as well as health care resource uses, over a patient's lifetime, in relation to their treatment.

Specifically, the research objectives of interest are:

  • Characterize the health and treatment trajectories of patients with COPD from diagnosis to death.
  • Assess clinical outcomes and health care resource use following moderate to severe COPD exacerbations (in the first year of follow-up), combined and stratified by severity of exacerbation (mild vs. severe).
  • Characterize the health and treatment trajectories of patients with COPD between and within each treatment-bound time period (i.e. while on mono-, dual-, or triple-therapy).
  • Describe the treatment patterns and burden of disease by different treatment groups at baseline (first year of follow-up).
  • Describe burden of disease in different treatment groups, by treatment at baseline.
  • Assess the impact of different treatment algorithms on patient, specifically on time to exacerbations and survival.
  • Describe the association of early vs delayed treatment after COPD diagnosis with Fixed-Dose Combination (FDC) Triple and resource utilization/cost-saving.
  • Describe the association of specific co-morbidities and exacerbations.
  • Explore association of biomarkers with exacerbation risk, if available.

Availability of Results: study in progress

Client: Janssen Inc.

Project ID: P2020-070/2021 0970 231 000

Research Question/Objectives: The study aim is to estimate the incidence and prevalence of patients with prostate cancer who fall into one of the four disease states.

Specifically, the research objectives of this study are:

  • Characterize the distribution of patients with prostate cancer in Ontario, through disease diagnosis and localized disease states: Localized -non-metastatic castration resistant (nmCRPC), metastatic, castration sensitive (mCSPC), metastatic castration resistant (mCRPC).
  • Demonstrate the economic burden of illness through health resource utilization cost.

Availability of Results: study in progress

Client: Astellas/University of Toronto

Project ID: P2020-081/2022 0970 258 000

Research Question/Objectives: What was the treatment pattern in men ≥ 66 years of age treated for lower urinary tract symptoms (LUTS) who received a prescription for overactive bladder (OAB)-specific medication or benign prostatic enlargement (BPE)-specific medication between 2009-2018, in Canada?

The specific objectives separately for OAB group and BPE group include:

  • Describe initial and subsequent management of LUTS.
  • Identify factors associated with change from initial therapy.
  • Characterize patient demographics and comorbidities.
  • Characterize healthcare utilization and healthcare-related costs and compare to a propensity score-matched cohort.
  • For OAB group, compare time to change in therapy for men who began OAB medication prior to May 28, 2015 (public insurance plan listing date for mirabegron), with those who began OAB medication on/after May 28, 2015, overall and by medication subgroups (β3-agonist vs. antimuscarinic).

Availability of Results: study in progress

Client: Sunnybrook Research Institute/HOPE Research Centre

Project ID: P2020-078/2022 0970 259 000

Research Question/Objectives: The client is looking for Canadian specific costs of various resources associated with three types of cancers for a model that requires cost, outcomes, and patient inputs.

Cost, outcomes, and patient inputs and utilization rates of various resources will be identified for the following cohorts of cancers:

  • Breast cancer
  • Metastatic non-small cell lung cancer
  • Mantle cell lymphoma.

Availability of Results: study in progress